Skip to main content

Table 4 Published studies on immunotherapy response in syngeneic murine models

From: Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer

Reference Model Tumor cells Inoculated Tumor size (mm3) Time to start treating (d) Outcome
Kim et al. PNAS 2014 4T1 5.00E6 400 11 Tumor eradication with PD-1/CTLA-4 at day 15
CT26 5.00E6 400 11 Tumor eradication with PD-1/CTLA-4 at day 15
Lian et al Sci Rep 2019 4T1 1.00E5 Not reported 24 PD-L1/CD74 dual blockade reduced lung metastasis
Clift et al. Cancer Res 2019 4T1/EMT6 1.00E5 100-150 Not reported PD-L1 blockade +PVHA inhibited tumor growth
Sun et al. Mol Cancer Ther 2020 4T1 1.00E6 100-150 3 CTLA-4 and PD-1 blockade promoted T cell infiltration
Xie et al. J Immunother Cancer 2018 4T1 5.00E6 <200 5,8 AngII blockade enhances sensitivity to CTLA-4/PD-1 treatment.
Xu et al. Clin Cancer Res 2017 EMT6 5.00E6 Not reported Not reported NHS-muIL12 and avelumab combination therapy enhanced antitumor efficacy relative to either monotherapy
Knudson et al. Oncoimmunology 2018 EMT6 2.50E5 50-100 Not reported Bifunctional checkpoint inhibitor of TGFβRII linked to the C-terminus of human anti-PD-L1 heavy chain reduced tumor burden.
4T1 5.00E4 50-100 Not reported
Zippelius et al. Cancer Immunol Res 2015 EMT6 2.50E5 Not reported 16 PD-L1 overexpression mediates acquired resistance to agonistic anti-CD40 treatment.
MC38 1.00E6 Not reported 16
Lewis et al. Oncoimmunology 2017 EMT6 1.50E6 Not reported 7 IL-21 inhibition with CTLA4 blockade promoted tumor regression compared to monotherapy.
Li et al. Cancer Cell 2018 4T1 5.00E4 <200 6 A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degradation.
EMT6 5.00E4 <200 6
Liu et al. Cancer Discovery 2016 4T1.2 2.00E4 40-80 16 Neo-adjuvant PD-1/CD-137 therapy had better efficacy than adjuvant
4T1.2 5.00E4 40-80 10 Increase in tumor-specific CD8+ T cells after neoadjuvant anti-PD-1+anti-CD137 therapy
E0771 5.00E4 40-80 16-18 Neo-adjuvant PD-1+CD-137 therapy had better efficacy than adjuvant.
Liu et al. Oncoimmunology 2019 E0771 2.00E5 50 10 Guadecitabine was similarly effective in the E0771 model of murine breast carcinoma. Finally, we found that guadecitabine in combination with AIT resulted in prolonged survival in both 4 T1 and E0771 breast cancer models.
4T1 5.00E4 50 10
Kasikara et al. Cancer Res 2019 E0771 1.00E5 Not reported 10 Combination of TAM inhibitor (BMS-777607) and anti-PD-1 improved tumor efficacy by altering the TME.
Messenheimer et al. Clin Cancer Res 2017 MMTV-PyMT 1.00E6 <50 7 Sequential combination of anti-OX40 and anti-PD-1 increased efficacy.
Nolan et al. Sci Transl Med 2017 MMTV-cre/Brca1fl/fl /p53+/- 4.00E4 100 21 Cisplatin treatment combined with dual anti–PD-1 and anti-CTLA-4 therapy substantially augmented antitumor immunity in Brca1-deficient mice.
Young et al. Plos One 2016 MMTV-PyMT 1.00E6 Not reported 14 Combination treatment with anti-CTLA4, anti-OX40 and radiation resulted in significantly extended survival.